Magenta Therapeutics, Inc. (MGTA) Bundle
A Brief History of Magenta Therapeutics, Inc. (MGTA)
Foundation and Early Development
Magenta Therapeutics, Inc. was founded in 2015, emerging from the biotechnology sector focused on developing medicines that enable curative therapies through targeted conditioning.
Initial Public Offering (IPO)
In May 2018, Magenta Therapeutics went public, raising approximately $95 million in its initial public offering. The stock was priced at $15 per share on the NASDAQ.
Financial Performance
By the end of 2020, Magenta’s revenue was reported at $9.6 million, mainly from collaborations and research funding, with a reported net loss of $50.1 million.
Key Partnerships
In 2019, the company entered into a partnership with Novartis, primarily focusing on developing novel conditioning regimens aimed at enhancing cell therapies. The collaboration was valued at approximately $75 million.
Product Pipeline
Magenta Therapeutics has a robust pipeline aimed at various therapeutic areas. As of 2021, the following candidates were in different stages of clinical development:
| Product Candidate | Indication | Stage of Development | Expected Milestone |
|---|---|---|---|
| MGTA-145 | Stem Cell Transplant Conditioning | Phase 2 | 2023 |
| MGTA-117 | Targeted Conditioning for cell therapies | Phase 1 | 2024 |
| MGTA-456 | Gene Therapy Conditioning | Preclinical | 2025 |
Recent Developments
In 2023, Magenta Therapeutics reported a funding round that raised $30 million to advance its pipeline and further research initiatives. The company's total assets were estimated to be around $50 million as of the second quarter of 2023.
Market Position and Challenges
As of 2023, Magenta's market capitalization stood at approximately $300 million. The company has faced challenges concerning product development timelines and funding but continues to work on strategic partnerships to enhance its research and development efforts.
Financial Overview
The financial status of Magenta Therapeutics as of 2023 includes:
| Financial Metric | Amount |
|---|---|
| Cash and Cash Equivalents | $35 million |
| Total Revenue (2022) | $10.2 million |
| Net Loss (2022) | $55 million |
| Research and Development Expenses | $40 million |
| General and Administrative Expenses | $15 million |
Future Outlook
Looking ahead, Magenta Therapeutics aims to advance its clinical programs by focusing on high-impact therapies and potential market expansions. The estimated market opportunity for cell therapy conditioning is projected to reach $5 billion by 2025.
A Who Owns Magenta Therapeutics, Inc. (MGTA)
Major Shareholders
Major Shareholders
As of the most recent proxy statement filed in 2023, the following institutions and insiders hold significant stakes in Magenta Therapeutics, Inc. (MGTA):
| Shareholder Name | Ownership Percentage (%) | Number of Shares Owned | Date of Latest Filing |
|---|---|---|---|
| BlackRock, Inc. | 10.2 | 2,500,000 | March 2023 |
| Vanguard Group, Inc. | 9.5 | 2,250,000 | March 2023 |
| Federated Hermes, Inc. | 6.8 | 1,600,000 | March 2023 |
| Hillhouse Capital Management | 5.3 | 1,200,000 | March 2023 |
| Insider Ownership | 4.9 | 1,150,000 | March 2023 |
Insider Holdings
Key executives and board members also own shares in Magenta Therapeutics, which impacts overall ownership structure:
| Name | Position | Shares Owned | Ownership Percentage (%) |
|---|---|---|---|
| Jason Gardner | CEO | 300,000 | 1.2 |
| Andrew P. Flanagan | CFO | 150,000 | 0.6 |
| Mark J. S. Conover | Board Member | 100,000 | 0.4 |
| Rita A. Ghosh | Board Member | 50,000 | 0.2 |
Market Capitalization and Stock Performance
The market capitalization of Magenta Therapeutics as of October 2023 is approximately:
| Market Cap ($ millions) | Current Stock Price ($) | 52-Week High ($) | 52-Week Low ($) |
|---|---|---|---|
| 250 | 5.00 | 7.50 | 3.00 |
Recent Financial Performance
Recent financial metrics indicate the company's performance in the fiscal year:
| Fiscal Year | Total Revenue ($ millions) | Net Income ($ millions) | Operating Expenses ($ millions) |
|---|---|---|---|
| 2022 | 15.0 | -25.0 | 40.0 |
| 2023 (Project Year) | 20.0 (projected) | -20.0 (projected) | 45.0 (projected) |
Institutional Ownership Trends
Trends in institutional ownership reveal fluctuations over time:
| Year | Institutional Ownership (%) | Change from Previous Year (%) |
|---|---|---|
| 2021 | 55.0 | - |
| 2022 | 58.0 | +3.0 |
| 2023 | 61.0 | +3.0 |
Magenta Therapeutics, Inc. (MGTA) Mission Statement
Company Overview
Magenta Therapeutics, Inc. is focused on developing transformative medicines for patients undergoing hematopoietic stem cell transplantation (HSCT). The company aims to enable better outcomes through its proprietary technology platform.
Mission Statement
The mission of Magenta Therapeutics is to improve the lives of patients through the development of innovative therapies and technologies to optimize stem cell transplantation, making it safer and more effective.
Core Values
- Innovation: Pioneering new solutions in stem cell therapies.
- Patient-Centricity: Keeping patient welfare at the forefront of our operations.
- Teamwork: Collaborating across disciplines to drive success.
- Integrity: Upholding ethical standards in all endeavors.
Strategic Goals
Magenta's strategic goals include:
- Advancing clinical trials of its leading therapeutic candidates.
- Expanding partnerships with leading healthcare institutions.
- Enhancing the understanding of HSCT and its applications.
- Driving financial growth through innovative product development.
Recent Financial Data
| Financial Metric | Amount (USD) |
|---|---|
| Market Capitalization | Approximately $65 million (as of Q3 2023) |
| 2022 Revenue | $2.1 million |
| 2023 Projected Revenue | $3.5 million |
| 2022 Net Income (Loss) | $(32.0) million |
| Cash and Cash Equivalents | $80 million (as of Q3 2023) |
| R&D Expenses (2022) | $25 million |
Key Therapeutic Candidates
Magenta has several therapeutic candidates in its pipeline aimed at improving HSCT outcomes:
- MGTA-145: A stem cell mobilization agent.
- MGTA-456: A targeted conditioning product for transplant.
- MGTA-117: A potential therapy for sickle cell disease.
Collaborations and Partnerships
Magenta Therapeutics collaborates with various academic institutions and biopharmaceutical companies to enhance its research capabilities:
- Partnership with Stanford University for clinical research.
- Collaboration with U.S. FDA for regulatory guidance.
- Strategic alliances with global biotech firms for expanded reach.
Outlook and Future Directions
With a focus on advancing its pipeline candidates, Magenta is committed to achieving regulatory approvals and enhancing the treatment landscape for patients in need of HSCT. The company continues to seek opportunities for growth through innovation and collaboration.
How Magenta Therapeutics, Inc. (MGTA) Works
Company Overview
Magenta Therapeutics, Inc. is a biotechnology company focused on developing therapies that enable curative treatments for patients with serious diseases. The company aims to revolutionize stem cell-based therapies by leveraging its proprietary technology platform.
Business Model
Magenta's business model is centered on the development of its pipeline of innovative therapies. The company focuses primarily on:
- Cell therapy
- Gene therapy
- Transplantation therapies
Financial Performance
According to the most recent quarterly report, Magenta Therapeutics reported the following financial data as of Q3 2023:
| Financial Metric | Amount (in millions USD) |
|---|---|
| Revenue | 0.00 |
| Operating Expenses | 9.20 |
| Net Loss | 8.50 |
| Cash and Cash Equivalents | 37.00 |
Pipeline
Magenta Therapeutics' pipeline includes several key programs:
- MGTA-145
- MGTA-117
- MGTA-456
The following table outlines the current status of these programs:
| Program | Indication | Phase |
|---|---|---|
| MGTA-145 | Sickle cell disease | Phase 2 |
| MGTA-117 | Multiple myeloma | Phase 1 |
| MGTA-456 | Bone marrow transplant | Preclinical |
Strategic Partnerships
Magenta Therapeutics has entered into strategic partnerships to further its research and development efforts. Some notable collaborations include:
- Partnership with leading research institutions
- Collaboration with pharmaceutical companies for clinical trials
Market Analysis
The biotechnology sector has seen significant growth, with the global market size estimated at $627.6 billion in 2021 and projected to reach $2.44 trillion by 2028. Magenta operates within this expanding market, focusing on niche opportunities in cell and gene therapies.
Investor Information
As of October 2023, Magenta Therapeutics’ stock price is approximately $1.50 per share. The company's market capitalization is around $100 million.
Recent Developments
Recent developments include:
- Completion of a Phase 1 trial for MGTA-145
- Announcing new preclinical data for MGTA-456
- Expansion of the research team to enhance R&D capabilities
How Magenta Therapeutics, Inc. (MGTA) Makes Money
Revenue Streams
Magenta Therapeutics primarily generates revenue through the development of innovative therapies aimed at diseases that necessitate stem cell transplants. The focus lies in enhancing the efficiency and safety of these treatments.
Partnerships and Collaborations
Magenta Therapeutics has engaged in strategic partnerships to bolster its research and development efforts. Financial details often include upfront payments, milestone payments, and royalties.
| Partnership | Year Established | Upfront Payment | Potential Milestones | Royalty Rate |
|---|---|---|---|---|
| Celgene Corporation | 2018 | $25 million | $200 million | 8-10% |
| Novartis AG | 2020 | $15 million | $150 million | 7-9% |
Grant Funding
The company also seeks grant funding from governmental and non-profit organizations to support its research initiatives. In 2022, the company received approximately $5 million in grants.
Stock Performance
As a publicly traded company, Magenta's revenue is also influenced by its stock performance. As of October 2023, MGTA shares are trading at approximately $3.50, with a market capitalization of around $150 million.
Product Pipeline
Magenta's pipeline includes several candidates that aim to address unmet medical needs in the field of stem cell biology. For example:
| Product Candidate | Indication | Phase | Projected Market Size |
|---|---|---|---|
| MGTA-145 | Sickle Cell Disease | Phase 2 | $1.2 billion |
| MGTA-117 | Acute Myeloid Leukemia | Phase 1/2 | $500 million |
Intellectual Property
Magenta holds multiple patents related to its therapeutic approaches. Licensing these patents can result in additional revenue streams.
Market Analysis
The global stem cell therapy market is projected to reach approximately $20 billion by 2025, offering substantial growth potential for Magenta's business model.
Financial Overview
For the fiscal year 2022, Magenta Therapeutics reported:
| Financial Metric | 2022 Amount |
|---|---|
| Revenue | $10 million |
| Net Loss | $30 million |
| Cash Position | $50 million |
Future Prospects
The company aims to further its pipeline candidates and increase partnerships, which could enhance its revenue generation capabilities as it progresses through clinical trials.
Magenta Therapeutics, Inc. (MGTA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support